Melanoma patients monitored years after experimental combo therapy

NCT ID NCT06848088

First seen Sep 30, 2025 · Last updated May 22, 2026 · Updated 31 times

Summary

This study follows 48 people with advanced melanoma who previously received the experimental drug combination fianlimab plus cemiplimab in an earlier trial. No new treatment is given; researchers track cancer status, overall health, and any late side effects over time. The goal is to understand the long-term safety and effectiveness of the prior therapy.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MELANOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • California Pacific Medical Center

    San Francisco, California, 94115, United States

  • Cancer & Hematology Centers of Western Michigan

    Grand Rapids, Michigan, 49546, United States

  • Henry Ford Hospital

    Detroit, Michigan, 48202, United States

  • Sarah Cannon Research Institute

    Nashville, Tennessee, 37203, United States

  • South Texas Oncology And Hematology

    San Antonio, Texas, 78229, United States

  • St. Vincent's University Hospital

    Dublin, D04 T6F4, Ireland

  • The Angeles Clinic and Research Institute - West Los Angeles Office

    Los Angeles, California, 90025, United States

  • University of Colorado Anschutz Medical Campus

    Aurora, Colorado, 80045, United States

Conditions

Explore the condition pages connected to this study.